Jiang, Hanfang http://orcid.org/0000-0002-3502-7073
Li, Huiping http://orcid.org/0000-0002-3331-647X
Song, Guohong
Di, Lijun
Shao, Bin
Yan, Ying
Liu, Xiaoran
Chen, Yifei
Zhang, Ruyan
Ran, Ran
Liu, Yaxin
Gui, Xinyu
Wang, Nan
Wang, Huan
Article History
Received: 10 December 2022
Accepted: 11 February 2023
First Online: 6 March 2023
Declarations
:
: HPL received some part of the study drug for this trial from Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co. Ltd. All other authors declare that they have no potential conflicts of interest to disclose.
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Peking University Cancer Hospital (ID:2017YJZ08).
: Informed consent was obtained from all individual participants included in the study.
: Patients signed an informed consent form regarding the publication of their data.